Winberg Carter, Prager Ross, Kim Chong Sung, Meyer Matthew, Arntfield Robert
Division of Critical Care, Western University, London, ON, Canada.
Decision Support Analyst, London Health Sciences Centre, London, ON, Canada.
Medicine (Baltimore). 2025 Apr 25;104(17):e41959. doi: 10.1097/MD.0000000000041959.
Persistently increasing healthcare spending, paired with growing healthcare demand, highlights the need to identify mechanisms for cost savings. Chest radiography (CXR) is commonly performed following intrathoracic procedures to rule out pneumothorax (PTX) even if the clinical pretest probability is low. However, lung ultrasound (LUS) is known to have superior sensitivity, possibly representing a promising cost-saving tool. In response, we conducted an economic analysis comparing LUS and CXR to exclude PTX after invasive intrathoracic procedures.
A retrospective review of the radiology case-costing center was performed at an academic cardiothoracic surgical institution to identify the activity and cost of CXRs performed to rule out PTX following intrathoracic procedures. This cost was then compared to the theoretical cost of LUS.
CXRs performed to rule out iatrogenic PTX were common with 22,274 radiographs completed and were economically burdensome, with an associated cost of $1.4 million. Portable CXR cost $75.46 per test, while CXR posteroanterior/lateral costs $41.64. Comparatively, LUS cost $38.38. Implementation would lead to cost savings of $559,537.10 or $41.58, on average, per patient.
Given the superiority of LUS in terms of sensitivity and accuracy for PTX diagnosis, these findings underscore the compelling rationale for its broader integration into clinical practice.
医疗保健支出持续增加,再加上医疗需求不断增长,凸显了确定成本节约机制的必要性。即使临床预检概率较低,在胸腔内手术后通常也会进行胸部X光检查(CXR)以排除气胸(PTX)。然而,已知肺部超声(LUS)具有更高的敏感性,可能是一种很有前景的成本节约工具。为此,我们进行了一项经济分析,比较LUS和CXR在侵入性胸腔内手术后排除PTX的情况。
在一家学术性心胸外科机构对放射科病例成本核算中心进行回顾性研究,以确定胸腔内手术后为排除PTX而进行的CXR检查的活动和成本。然后将该成本与LUS的理论成本进行比较。
为排除医源性PTX而进行的CXR检查很常见,共完成了22274张X光片,且成本高昂,相关成本为140万美元。便携式CXR每次检查成本为75.46美元,而后前位/侧位CXR成本为41.64美元。相比之下,LUS成本为38.38美元。实施LUS将平均为每位患者节省559537.10美元或41.58美元。
鉴于LUS在PTX诊断的敏感性和准确性方面具有优势,这些发现强调了将其更广泛地纳入临床实践的令人信服的理由。